PDS Biotech Leadership to Participate in March Conferences

Core Viewpoint - PDS Biotechnology Corporation is actively engaging with investors and the scientific community through upcoming presentations, highlighting its focus on immunotherapy for cancer treatment, particularly its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [1][3]. Presentation Details - PDS Biotech's CEO, Frank Bedu-Addo, will present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025, at 2:30 PM ET [2]. - The company will also present at the 2025 CAGLA NeauxCancer Conference in New Orleans on March 28-29, 2025, during the Innovation Track session at 4:00 PM ET [2]. Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on transforming immune responses to target and kill cancers [3]. - The company has initiated a pivotal clinical trial for its lead investigational immunotherapy, Versamune® HPV, in combination with a standard immune checkpoint inhibitor and a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate [3].